Insight into Antiacetylcholinesterase Potential of Modified Chalcones: Synthesis, Characterization, in Vitro, and Computational Investigation
Abstract
Neurological disorders remain a major challenge in modern medicine due to the brain’s complexity and the limited efficacy of genetic therapies. Acetylcholinesterase (AChE) is a key target in the treatment of Alzheimer’s disease. In this study, a series of modified 4‐benzyloxychalcone derivatives (9a–j) were synthesized and structurally characterized using various spectroscopic techniques, including IR, 1H NMR, 13C NMR, and HRMS. Quantum chemical calculations, along with MM/GBSA and MM/PBSA analyses, were performed to evaluate the electronic properties and binding free energies of the compounds. All compounds met Lipinski’s criteria. Molecular docking and dynamics simulations revealed that compound 9c exhibited the most stable interaction with AChE (PDB ID: 4EYZ), supported by a strong binding profile. Additionally, the small HOMO–LUMO energy gap indicates the compounds' potent anticholinesterase capabilities via the POM/DFT approach. Furthermore, high hyperpolarizability and polarizability values suggest additional potential as pharmacophores. The derivatives demonstrated favorable binding with active site residues of the enzyme, suggesting their potential as effective AChE inhibitors. Overall, the findings indicate that benzyloxychalcones (9a–j) bind key amino acids in the 4EYZ binding pocket, highlighting their potential as candidates for Alzheimer’s disease treatment.
How strong is the evidence?
Evidence Hub reads this as a simulation / modelling, done in cell cultures (in vitro), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.